乳腺癌放疗两年后治疗相关毒性的全基因组关联研究
本研究在1,640例接受全乳放疗的乳腺癌患者中开展全基因组关联研究(GWAS),纳入18个欧洲和美国中心的前瞻性REQUITE队列,检测7,097,340个SNP与放疗后两年毒性终点的关联。8个SNP达到全基因组显著性,涉及乳头回缩、乳腺水肿、硬结和手臂淋巴水肿;本研究未能在预设显著性水平重复既往报道的与乳腺放疗毒性相关的SNP。
要点
- 乳头回缩≥2级与rs188287402相关(p=2.80×10-8)。
- 乳腺水肿≥2级与rs12657177、rs75912034、rs145328458和rs61966612相关。
- 手臂淋巴水肿≥1级与rs643644相关(p=3.54×10-8)。
核心结论
- 本GWAS为常见SNP与不同乳腺放疗毒性终点的显著关联提供了进一步证据。
- 本研究未能在预设显著性水平重复既往报道的与乳腺放疗毒性相关的SNP。
研究设计与样本
- 在1,640例具有完整SNP、临床、治疗和毒性数据的乳腺癌患者中开展GWAS,患者来自18个欧洲和美国中心的前瞻性REQUITE队列研究。
- 毒性数据采用CTCAE v4.0在基线、放疗结束时和年度随访时收集。
- 共检测7,097,340个SNP与毒性终点残差的关联,并对临床、治疗协变量和群体亚结构进行了校正。
主要发现
- 分位数-分位数图显示,p<5×10-5水平上与毒性的关联多于偶然预期。
- 8个SNP达到全基因组显著性。
- 乳头回缩≥2级与rs188287402变异相关(p=2.80×10-8)。
- 乳腺水肿≥2级与rs12657177(p=1.12×10-10)、rs75912034(p=1.12×10-10)、rs145328458(p=1.06×10-9)和rs61966612(p=1.23×10-9)相关。
- 硬结≥2级与rs77311050(p=2.54×10-8)和rs34063419(p=1.21×10-8)相关,手臂淋巴水肿≥1级与rs643644(p=3.54×10-8)相关。
关键数值与推荐
- 显著终点的遗传力估计范围为25%至39%。
- 8个SNP达到全基因组显著性,涉及乳头回缩、乳腺水肿、硬结和手臂淋巴水肿。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本研究未能在预设显著性水平重复既往报道的与乳腺放疗毒性相关的SNP。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Up to a quarter of breast cancer patients treated by surgery and radiotherapy experience clinically significant toxicity. If patients at high risk of adverse effects could be identified at diagnosis, their treatment could be tailored accordingly. This study was designed to identify common single nucleotide polymorphisms (SNPs) associated with toxicity two years following whole breast radiotherapy. MATERIALS AND METHODS: A genome-wide association study (GWAS) was performed in 1,640 breast cancer patients with complete SNP, clinical, treatment and toxicity data, recruited across 18 European and US centres into the prospective REQUITE cohort study. Toxicity data (CTCAE v4.0) were collected at baseline, end of radiotherapy, and annual follow-up. A total of 7,097,340 SNPs were tested for association with the residuals of toxicity endpoints, adjusted for clinical, treatment co-variates and population substructure. RESULTS: Quantile-quantile plots showed more associations with toxicity above the p < 5 × 10-5 level than expected by chance. Eight SNPs reached genome-wide significance. Nipple retraction grade ≥ 2 was associated with the rs188287402 variant (p = 2.80 × 10-8), breast oedema grade ≥ 2 with rs12657177 (p = 1.12 × 10-10), rs75912034 (p = 1.12 × 10-10), rs145328458 (p = 1.06 × 10-9) and rs61966612 (p = 1.23 × 10-9), induration grade ≥ 2 with rs77311050 (p = 2.54 × 10-8) and rs34063419 (p = 1.21 × 10-8), and arm lymphoedema grade ≥ 1 with rs643644 (p = 3.54 × 10-8). Heritability estimates across significant endpoints ranged from 25% to 39%. Our study did not replicate previously reported SNPs associated with breast radiation toxicity at the pre-specified significance level. CONCLUSIONS: This GWAS for long-term breast radiation toxicity provides further evidence for significant association of common SNPs with distinct toxicity endpoints.
引用
- Jandu HK, Veal CD, Fachal L, et al. Genome-wide association study of treatment-related toxicity two years following radiotherapy for breast cancer. Radiother Oncol. 2023. PMID: 37437607. doi:10.1016/j.radonc.2023.109806
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。